EQUITY RESEARCH - ANALYST MEETING



BANGKOK CHAIN HOSPITAL

BCH TB

THAILAND / HEALTH CARE SERVICES

UNCHANGED

THB26.00 THB21.80 **UP/DOWNSIDE** +19.3% PRIOR TP **CHANGE IN TP**

TARGET PRICE **CLOSE**

THB26.00 **UNCHANGED TP vs CONSENSUS** +3.9%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	11,729	12,912	13,961	15,098
Net profit	1,406	1,861	2,104	2,386
EPS (THB)	0.56	0.75	0.84	0.96
vs Consensus (%)	-	3.2	1.4	3.6
EBITDA	2,802	3,395	3,757	4,169
Recurring net profit	1,406	1,861	2,104	2,386
Core EPS (THB)	0.56	0.75	0.84	0.96
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	(53.7)	32.3	13.0	13.4
Core P/E (x)	38.7	29.2	25.8	22.8
Dividend yield (%)	2.3	1.6	1.9	2.1
EV/EBITDA (x)	19.6	15.8	14.0	12.3
Price/book (x)	4.3	4.0	3.7	3.4
Net debt/Equity (%)	(4.4)	(11.8)	(18.7)	(25.2)
ROE (%)	11.2	14.2	14.9	15.6

Mar-23 Jun-23 Sep-23 25 30 20 20 15 10 10 5 (10)n (20)Relative to SET (THB) (%)

Share price performance	1 Month	3 Month	12 Month
Absolute (%)	0.0	2.8	15.3
Relative to country (%)	(0.7)	1.7	26.0
Mkt cap (USD m)			1,526
3m avg. daily turnover (USD m)			7.2
Free float (%)			50
Major shareholder	Chaleri	m Harnpha	nich (33%)
12m high/low (THB)		2	3.80/16.60
Issued shares (m)			2,493.75

Sources: Bloomberg consensus; FSSIA estimates

Key takeaways from analyst meeting

Highlights

- We have a positive view from the 4Q23 analyst meeting.
- Management targets a double-digit revenue growth in 2024 (vs our 10% growth estimate) with crucial drivers including.
 - 1. A 4% higher registered SSO members from 1.01m to 1.05m following a higher quota of the main hospitals (KH Bangkae and KH Prachachuen).
 - 2. More SSO services including sleep apnea treatments (which can reimburse sleep lab treatments of THB6,000-7,000 and CPAP machine of THB20,000) and a check-up package for members of above 35 years old. In addition, BCH plans to actively use mobile dental units to provide dental treatments (THB900/member/year).
 - 3. A double-digit growth in international patient revenue, especially
- A promising revenue trend in Jan-Feb 24 with the likelihood of a double-digit y-y growth and a higher net profit margin.
- For the update on the payment of RW>2 under the SSO scheme. BCH has received ten installments in 2023 and is waiting for the last two, which management still expects the SSO to pay at a rate of 12,000/RW. There will be a discussion on this issue with SSO on 22 Mar.
- As of 4Q23, outstanding accounts receivable (AR) for Covid treatments amounted to THB480m. BCH has set a 5% provision for it. In addition, around THB70m has had a statement from UCEP, implying a high potential to receive a full payment.
- Management commented on Kuwait's government policy to cut payment guarantees for citizens seeking treatment overseas. In this regard, BCH will see an impact given that Kuwait accounted for about 20-25% of Middle East patient volume and around 20% of the total international patient revenue. BCH expects the situation to improve after the Ramadan.
- KIH Vientiane and KIH Aranyaprathet should turn profitable by the end of this year.


Forecast and recommendation

- We forecast the core profit to jump by 33% to THB1.9b in 2024 on a lower FX loss from KIH Vientiane, lower provision expenses or revenue reversal related to Covid, a lower loss from the three new hospitals, and growth from more registered SSO members.
- Maintain BUY. BCH is trading at an attractive valuation of 29x 2024E P/E



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities: License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: 2024E core profit growth breakdown




Note: Applied 20% tax for each item Source: FSSIA estimates

Exhibit 2: 2024E key earnings growth assumptions

Key growth items	Assumptions
Absence of FX loss	BCH booked a THB151m FX loss from KIH Vientiane following the LAK's depreciation against the THB in 2023. We believe the FX loss will significantly reduce to only THB30-40m in 2024 as it has repaid the THB term loan.
Absence of provision expenses	BCH booked provision expenses and a revenue reversal related to Covid treatments totaling THB121m in 2023. We expect a provision expense to reduce to THB40-50m in 2024.
Turnaround of new hospitals	Expect three new hospital losses (excluding FX loss) to narrow from THB140m-150m in 2023 to THB60-70m in 2024.
Additional SSO members	Expect registered members to increase by 40k in 2024 with average revenue per head of THB3,900 and an EBITDA margin of 35-40% for additional SSO revenue.
Organic growth	Expect core profit growth of 10-12%, driven by higher revenue intensity from international patients.


Source: FSSIA estimates

Exhibit 3: Thai general patient revenue



Sources: BCH; FSSIA estimates

Exhibit 4: International patient revenue




Sources: BCH; FSSIA estimates

Exhibit 5: SSO revenue, yearly



Sources: BCH; FSSIA estimate

Exhibit 6: EBITDA margin



Sources: BCH; FSSIA estimate

Financial Statements

Bangkok Chain Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	18,827	11,729	12,912	13,961	15,098
Cost of goods sold	(12,772)	(8,116)	(8,678)	(9,300)	(9,969)
Gross profit	6,055	3,613	4,233	4,661	5,129
Other operating income	-	-	-	-	-
Operating costs	(1,946)	(1,755)	(1,822)	(1,939)	(2,052)
Operating EBITDA	5,059	2,802	3,395	3,757	4,169
Depreciation	(950)	(944)	(983)	(1,035)	(1,091)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	4,109	1,859	2,412	2,722	3,077
Net financing costs	(148)	(77)	(37)	(34)	(25)
Associates	0	1	1	1	1
Recurring non-operating income	84	102	106	111	117
Non-recurring items	0	0	0	0	0
Profit before tax	4,046	1,883	2,480	2,800	3,169
Tax	(888)	(405)	(496)	(560)	(634)
Profit after tax	3,157	1,479	1,984	2,240	2,535
Minority interests	(118)	(73)	(123)	(136)	(150)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	3,039	1,406	1,861	2,104	2,386
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	3,039	1,406	1,861	2,104	2,386
Per share (THB)					
Recurring EPS *	1.22	0.56	0.75	0.84	0.96
Reported EPS	1.22	0.56	0.75	0.84	0.96
DPS	1.40	0.50	0.35	0.41	0.46
Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Growth					
Revenue (%)	(12.0)	(37.7)	10.1	8.1	8.1
Operating EBITDA (%)	(50.6)	(44.6)	21.1	10.7	11.0
Operating EBIT (%)	(56.2)	(54.8)	29.8	12.9	13.1
Recurring EPS (%)	(55.6)	(53.7)	32.3	13.0	13.4
Reported EPS (%)	(55.6)	(53.7)	32.3	13.0	13.4
Operating performance					
Gross margin inc. depreciation (%)	32.2	30.8	32.8	33.4	34.0
Gross margin exc. depreciation (%)	37.2	38.9	40.4	40.8	41.2
Operating EBITDA margin (%)	26.9	23.9	26.3	26.9	27.6
Operating EBIT margin (%)	21.8	15.8	18.7	19.5	20.4
Net margin (%)	16.1	12.0	14.4	15.1	15.8
Effective tax rate (%)	22.0	21.5	20.0	20.0	20.0
Dividend payout on recurring profit (%)	114.9	88.7	46.9	48.7	48.5
Interest cover (X)	28.4	25.4	67.2	84.4	127.4
Inventory days	12.3	17.0	15.0	15.0	15.0
Debtor days	49.3	37.0	23.7	21.9	20.3
Creditor days	41.0	67.9	67.2	67.2	67.2
Operating ROIC (%)	21.4	10.9	15.3	17.4	19.8
ROIC (%)	21.0	10.9	15.2	17.2	19.5
ROE (%)	23.9	11.2	14.2	14.9	15.6
ROA (%)	14.2	8.2	11.0	11.7	12.3
Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	9,372	7,976	8,710	9,330	9,994
odon padont revenue	3,512	1,310	0,710	5,550	5,554
SSO patient revenue	3,371	3,850	4,202	4,631	5,104

Sources: Bangkok Chain Hospital; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
Recurring net profit	3,039	1,406	1,861	2,104	2,386
Depreciation	950	944	983	1,035	1,09
Associates & minorities	-	-	-	-	
Other non-cash items	24	114	117	136	150
Change in working capital	1,459	1,563	15	29	3.
Cash flow from operations	5,471	4,027	2,976	3,304	3,65
Capex - maintenance	(984)	(896)	(897)	(977)	(1,057
Capex - new investment Net acquisitions & disposals	2	4	0	0	(
Other investments (net)	-	-	-	-	'
Cash flow from investing	(982)	(892)	(897)	(977)	(1,057
Dividends paid	(3,491)	(1,247)	(873)	(1,024)	(1,157
Equity finance	0	0	0	0	(1,101
Debt finance	(3,153)	(2,310)	(200)	0	
Other financing cash flows	(462)	(32)	(68)	(75)	(82
Cash flow from financing	(7,106)	(3,590)	(1,141)	(1,099)	(1,239
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
Net other adjustments	0	0	0	0	(
Movement in cash	(2,616)	(455)	938	1,228	1,36
Free cash flow to firm (FCFF)	4,645.31	3,230.18	2,131.12	2,381.71	2,655.6
Free cash flow to equity (FCFE)	875.07	791.94	1,810.78	2,251.66	2,518.1
Per share (THB)					
FCFF per share	1.86	1.30	0.85	0.96	1.0
FCFE per share	0.35	0.32	0.73	0.90	1.0
Recurring cash flow per share	1.61	0.99	1.19	1.31	1.4
Salance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
, , , , , , , , , , , , , , , , , , ,					
Fangible fixed assets (gross)	20,274	20,884	21,787	22,765	23,82
Less: Accumulated depreciation	(7,992)	(8,639)	(9,622)	(10,657)	(11,748
Fangible fixed assets (net)	12,282 425	12,244 440	12,165 440	12,108 440	12,07 44
ntangible fixed assets (net) ong-term financial assets	425	440	440	440	44
nvest. in associates & subsidiaries	32	28	28	28	2
Cash & equivalents	2,640	2,185	3,123	4,351	5,71
A/C receivable	1,539	839	839	839	83
nventories	362	306	328	352	37
Other current assets	2,294	1,513	1,665	1,800	1,94
Current assets	6,835	4,843	5,956	7,343	8,87
Other assets	223	176	176	176	17
Total assets	19,796	17,731	18,764	20,094	21,59
Common equity	12,445	12,594	13,582	14,662	15,89
Minorities etc.	1,065	1,110	1,166	1,227	1,29
Total shareholders' equity	13,510	13,704	14,748	15,890	17,18
Long term debt	3,888	1,497	1,297	1,297	1,29
Other long-term liabilities	163	187	187	187	18
ong-term liabilities	4,051	1,684	1,484	1,484	1,48
VC payable	1,300	1,368	1,467	1,576	1,69
Short term debt	0	81	81	81	8
Other current liabilities	935	894	984	1,064	1,15
Current liabilities	2,235	2,342	2,532	2,721	2,92
Total liabilities and shareholders' equity	19,796	17,731	18,764	20,094	21,59
Net working capital	1,959	396	381	352	32
nvested capital Includes convertibles and preferred stock which is beir	14,921	13,284	13,190	13,103	13,03
modes convenibles and preferred stock which is being	ig ireated as debt				
Per share (THB)					
Book value per share	4.99	5.05	5.45	5.88	6.3
Fangible book value per share	4.82	4.87	5.27	5.70	6.2
Financial strength					
Net debt/equity (%)	9.2	(4.4)	(11.8)	(18.7)	(25.2
Net debt/total assets (%)	6.3	(3.4)	(9.3)	(14.8)	(20.
Current ratio (x)	3.1	2.1	2.4	2.7	3
CF interest cover (x)	6.9	11.3	49.4	68.1	101.
/aluation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	17.9	38.7	29.2	25.8	22
Recurring P/E @ target price (x) *	21.3	46.1	34.8	30.8	27
Reported P/E (x)	17.9	38.7	29.2	25.8	22
Dividend yield (%)	6.4	2.3	1.6	1.9	2
	4.4	4.3	4.0	3.7	3
Price/book (x)			4.4	2.0	3
• •	4.5	4.5	4.1	3.8	3
Price/tangible book (x)	4.5 11.2	4.5 19.6	4.1 15.8	14.0	
Price/book (x) Price/tangible book (x) EV/EBITDA (x) ** EV/EBITDA @ target price (x) **					12. 14.

Sources: Bangkok Chain Hospital; FSSIA estimates

Bangkok Chain Hospital PCL (BCH TB)

FSSIA ESG rating

★ ★ ★

Exhibit 7: FSSIA ESG score implication

39.71 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 8: ESG – peer comparison

	FSSIA			Domes	stic ratings	;		Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Υ	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	_	_	_	_	1	2
GHG scope 2 location-based	_	_	_	_	_	_	5	6
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	Yes						
Total energy consumption	_	_	_	_	_	_	10	12
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	10	12
Fuel used - natural gas	_	_	_	_	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 202
Fuel used - crude oil/diesel	No	N						
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Ye
Hazardous waste	_	_	_	_	_	_	_	
Total waste	_	_	_	_	_	_	_	
Waste recycled	_	_	_	_	_	_	_	
Waste sent to landfills	_	_	_	_	_	_	_	
Environmental supply chain management	No	Υe						
Water policy	No	No	No	No	No	No	Yes	Ye
Water consumption	_	_	_	_	_	_	_	-
Social								
Human rights policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Policy against child labor	No	Ye						
Quality assurance and recall policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Y
Consumer data protection policy	No	1						
Equal opportunity policy	Yes	Y						
Gender pay gap breakout	No	١						
Pct women in workforce	_	_	_	_	_	_	_	
Pct disabled in workforce	_	_	_	_	_	_	_	
Business ethics policy	Yes	Y						
Anti-bribery ethics policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Y
Health and safety policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Υ
Lost time incident rate - employees	_	_	_	_	_	_	0	
Total recordable incident rate - employees	_	_	_	_	_	_	0	
Training policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Υ
Fair remuneration policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Υ
Number of employees – CSR	_	_	_	_	_	_	8,597	8,8
Employee turnover pct	_	_	_	_	_	_	_	
Total hours spent by firm - employee training	_	_	_	_	_	_	_	54,7
Social supply chain management	No	Yes	Yes	Yes	Yes	Yes	Yes	Y
Governance								
Board size	10	10	10	12	12	12	12	
No. of independent directors (ID)	4	4	4	4	4	4	4	
No. of women on board	3	3	3	4	4	3	3	
No. of non-executive directors on board	5	5	5	5	5	5	5	
Company conducts board evaluations	Yes	Υ						
No. of board meetings for the year	6	5	6	5	5	6	6	
Board meeting attendance pct	93	94	90	96	100	99	94	,
Board duration (years)	_	_	_	_	_	_	_	
Director share ownership guidelines	No	1						
Age of the youngest director	28	29	30	29	30	31	32	
Age of the oldest director	72	73	74	75	76	77	78	
No. of executives / company managers	5	5	5	5	5	7	7	
No. of female executives	1	_	_	_	_	_	_	
Executive share ownership guidelines	No	1						
Size of audit committee	3	3	3	3	3	3	3	
No. of ID on audit committee	3	3	3	3	3	3	3	
Audit committee meetings	4	4	5	5	5	5	5	
Audit meeting attendance %	100	92	100	93	100	100	93	1
Size of compensation committee	0	0	0	0	0	0	0	
No. of ID on compensation committee	_	_	_	_	_	_	_	
No. of compensation committee meetings	_	_	_	_	_	_	_	
Compensation meeting attendance %	_	_	_	_	_	_	_	
Size of nomination committee	0	0	0	0	0	0	0	
No. of nomination committee meetings	_	_	_	_	_	_	_	
Nomination meeting attendance %	_	_	_	_	_	_	_	
Sustainability governance								
,	No	No	No		No	No		1

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	Jy .			Rating					
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the anr	ed on the com	transparent, rules-based npanies' Total Sustainabil pal Corporate Sustainabili anies within each industr	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of	Assessment (C ess than 45% ny are disqua	the annual S&P (CSA) for DJSI. Co of the S&P Glob ified. The constit iverse.	ompanies with al ESG Score	an S&P Globa of the highest	
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing be Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of the shareholders come key disque ependent direct related to CG	ility in Environmental and ransparency in Governand preemptive criteria, with ne board members and exist, and combined holding re ualifying criteria include: ctors and free float violation, social & environmental in parnings in red for > 3 years	ce, updated annually. two crucial conditions: kecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.					
CG Score by Thai nstitute of Directors Association (Thai IOD)	annually by Thailand (SE	the Thai IOD,	th in sustainable developr with support from the Sto ts are from the perspectiv s.	ck Exchange of	Good (80-89), and not rated f equitable treat	3 for Good (70 or scores belo ment of sharel 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (0 w 50. Weightings nolders (weight 2 osure & transpare	60-69), 1 for F s include: 1) th 5% combined	lass (60-69), ne rights; 2) an); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	e incorporated and sufficientle CG componer AGM proced and after the undifficient informate second assessery; and 3) openne	which shareholders' rights d into business operations y disclosed. All form imponents to be evaluated ann dures before the meeting (10%). (The first aution for voting; and 2) facilitations of Voting; and 2) facilitations of Voting; and Voting research Q&A. The third involve less, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be leetings; 2) transparency is the meeting minutes that			o four categories: r (80-89), and no		` ''	
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies d Declaration of Certification, in managers and	nt of key contree Certification eciding to becon Intent to kick off ncluding risk ass	Checklist include corruptions, and the monitoring a is good for three years. The a CAC certified member st fan 18-month deadline to subsessment, in place of policy are tablishment of whistleblowing ill stakeholders.)	nd developing of art by submitting a mit the CAC Checklist for nd control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on an risk is unma	assessment on aged. Source	isk rating provides an ove of how much of a compar s to be reviewed include corp her media, NGO reports/webs	ny's exposure to ESG orate publications and	more risk is un	managed, the	score is the sum higher ESG risk	is scored.	ed risk. The	
		ompany feedbac uality & peer rev	k, ESG controversies, issuer riews.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+	
ESG Book	positioned to the principle helps explain over-weighti	o outperform o of financial m n future risk-a	sustainable companies the over the long term. The materiality including inform djusted performance. Martith higher materiality and erly basis.	ethodology considers ation that significantly teriality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.					
MSCI		0	measure a company's mand laggards according to	,					nethodology to	
	AAA	8.571-10.00	0 Leader:	leading its industry in m	anaging the most o	ignificant ESC r	aka and annortuniti	20		
	AA	7.143-8.570	D Leader.	leading its industry in in	anaging the most s	ignincant ESG n	sks and opportunite	25		
	Α	5.714-7.142	2	a mixed or unexception	al track record of m	anaging the mos	et significant ESG ri	ske and apportu	nities relative to	
	BBB	4.286-5.713	-	industry peers	ar truck record of m	anaging the mo	or organicant 200 m	ono ana opporta	illico foldilivo to	
	BB	2.857-4.285								
	B CCC	1.429-2.856 0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	sure and failure t	o manage significar	nt ESG risks		
Moody's ESC				take into account ESC a	hipotivos in the s	Infinition and :	mplementation	f thoir strates	nolicies It	
Moody's ESG colutions	believes that	t a company ir	gree to which companies ntegrating ESG factors int or shareholders over the	to its business model and						
Refinitiv ESG rating	based on pu	blicly available	and objectively measure e and auditable data. The ata publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performa	nce and insufficie	nt degree of t		
S&P Global			ore is a relative score meanin the same industry clas				of ESG risks, op	portunities, ar	nd impacts	
Bloomberg	ESG Score		score is based on Bloor	ating the company's agg mberg's view of ESG fina the weights are determin	ıncial materiality.	The score is	a weighted gene	ralized mean	power mean)	
	ESG Disclos		Disclosure of a compan							

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
31-Mar-2021 20-Apr-2021 25-May-2021 14-Jul-2021	BUY BUY BUY BUY	20.00 23.00 24.00 28.00	05-Aug-2021 25-Oct-2022 09-Feb-2023 03-May-2023	BUY BUY BUY BUY	28.50 26.00 25.50 23.50	03-Aug-2023 03-Nov-2023 30-Jan-2024	BUY BUY BUY	22.50 24.50 26.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	всн тв	THB 21.80	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 14-Mar-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.